Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19

• Status: Active, not recruiting
• Trial end date: 2021-06-01

Summary

This is an open-label, multicenter, parallel-group, randomized, phase III trial that evaluates the efficacy and safety of hydroxychloroquine and favipiravir in the treatment of patients with possible or confirmed COVID-19 observed within the last 5 days. 1000 patients will be randomized in 2:1:2:2:2:1 ratio and divided into six groups.

• Phase: Phase 3

Details

• Lead Sponsor: Ministry of Health, Turkey
• Collaborators: Ankara City Hospital Bilkent; Ankara Training and Research Hospital; Ankara University; Ege University Hospital (Application and Research Center); Hacettepe University, Faculty of Medicine; Istanbul University; Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine; Istanbul University, Istanbul Faculty of Medicine; Kayseri City Hospital; Kocaeli Derince Education and Research Hospital; Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization; SB Istanbul Education and Research Hospital; Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey; Tepecik Training and Research Hospital; Umraniye Education and Research Hospital
• Treatments: Azithromycin; Favipiravir; Hydroxychloroquine